N.H. Nguyen ¹, D.N. Tran ², H. Lin ³, O. Romanov ², T. Thi Bich ², L.D.E. Ellerma ⁴, R. Del Pozo Sacristán ⁴

¹Department of Infectious diseases and Public health, Faculty of Animal sciences and veterinary medicine, Nonglam University, Linhtrung ward, Thuduc city, Hochiminh city, Vietnam. ²MSD Animal Health, Vietnam ³MSD Animal Health Innovation Pte Ltd, 1 Perahu Road, Singapore ⁴MSD Animal Health

Background

PRRSV, PCV2 and Mhyo are pathogens within porcine respiratory disease complex (PRDC). Vaccination is a key tool to control PRDC. Vaccination by intramuscular (IM) injection has been applied for many years. It has limitations such as: stressing the animal, affecting the quality of meat, risking iatrogenic disease transmission. Intradermal (ID) vaccination is an alternative way of application. This study compares the immune response and zootechnical performance after intradermal vaccination against PRRSV, PCV2, and Mhyo (ID Group) and intramuscular injection (IM Group), in finishers under standard farming conditions in Vietnam.

Material and Methods

In total, 200 five-day old pigs were randomly assigned to two different groups: Group 1 (ID-G; n=100) and Group 2 (IM-G; n=100). At 14 days of age, piglets were vaccinated against PRRSV; ID-G intradermally with PRIME PAC[®] PRRS using IDAL 3G and IM-G using a PRRS MLV vaccine intramuscularly. PCV2 and Mhyo vaccination: at 21 days of age; ID-G was vaccinated intradermally using IDAL 3G TWIN with Porcilis[®] PCV ID and Porcilis[®] M HYO ID ONCE vaccine while IM-G was vaccinated intramuscularly with a combined PCV2 and Mhyo vaccine. Pigs were weighed individually at 24, 35 and 175 days. Zootechnical parameters such as ADWG and Mortality rate were also recorded separately. Blood samples were collected (20 pigs/group) at 10, 70, 105 and 54 days and evaluated for antibody response for PRRS, PCV2 and Mhyo.

Table 1. Vaccines used in the study.						
Vaccine	ID Group	IM Group	Age			
PRRS	PRIME PAC™ PRRS¹0.2ml	PRRS MLV IM Vaccine 2ml	14 days			
PCV2	Porcilis® PCV ID ¹ 0.2ml	Combined PCV2+Mhyo Vaccine 1ml	21 days			
Mycoplasma hyopneumoniae	Porcilis® M HYO ID ONCE ¹ 0.2ml	Combined PCV2+Mhyo Vaccine 1ml	21 days			

Results

Performance of both groups showed no statistical difference (P>0.05) for both ADWG (ID-G: 0.637; IM-G: 0.636) and Mortality rate (ID-G: 4%; IM-G: 4%). Antibody titers for PRRSv revealed marked increase for both groups post vaccination but there was no statistical difference between two groups. Mhyo and PCV2 antibody titers for ID group were significantly higher compared with the IM group. Table 2. Impact on production parameters.

Group	Average weight at selling (Kg)	Days to market (day)	ADG (Kg/day)
ID	$103.22 \pm$	$175.18 \pm$	$0.637 \pm$
	20.37 a	24.19 a	0.140 a
IM	$103.17 \pm$	$177.35 \pm$	$0.636 \pm$
	19.76 a	19.31 a	0.131 a

*Values with different superscript within the same column are statistically significant (P<0.05)

Table 3. Antibody titers of piglets before and after vaccination

Time	PRE	2SV	M hyonn	eumoniae	p	CV2		
of	(vaccinate at 14 days		(vaccinate at 21 days		(vaccinate at 21 days of			
sampli	i of age)		of age)		age)			
ng	ID	IM	ID	IM	ID	IM Group		
	Group	Group	Group	Group	Group			
Before vaccination								
10	$0.641 \pm$	$0.476 \pm$	0.725 ±	$0.655 \pm$	$6.423 \pm$	6.152 ±		
days	0.512a	0.392a	0.603a	0.661a	1.521 a	1.478a		
After vaccination								
70	1.591 ±	$1.589 \pm$	0.153 ±	$0.077 \pm$	$6.978 \pm$	5.775 ±		
days	0.845a	0.841a	0.197b	0.130a	1.328 b	1.015a		
105	$1.557 \pm$	$1.429 \pm$	$0.107 \pm$	$0.021 \pm$	$6.508 \pm$	$5.632 \pm$		
days	0.539a	0.630a	0.143b	0.051a	1.138 b	0.847a		
154	$1.030 \pm$	$1.250 \pm$	$0.493 \pm$	$0.468 \pm$	$5.565 \pm$	$5.197 \pm$		
days	0.599a	0.602a	0.445a	0.461a	1.320 a	1.782a		

*Values with different superscript within the same column are statistically significant (P<0.05)

Discussion and conclusion

The study showed that intradermal route of vaccinating animals with PRRSv, PCV2 and M. hyopneumoniae was able to show similar response with that of intramuscular route. Administering vaccines via this route has additional benefits associated with needle-free vaccination such as reducing stress and improving farm biosecurity.

¹.Dalmau A, Sánchez-Matamoros A, Molina JM, Xercavins A, Varvaró-Porter A, Muñoz I, Moles X, Baulida B, Fàbrega E, Velarde A, Pallisera J, Puigredon A and Contreras-Jodar A, 2021. Intramuscular vs. Intradermic Needle-Free Vaccination in Piglets: Relevance for Animal Welfare Based on an Aversion Learning Test and Vocalizations. Front. Vet. Sci. 8:715260. doi: 10.3389/fvets.2021.715260.

².Madapong, A., Saeng-chuto, K., Tantituvanont, A., Nilubol, D., 2021. Safety of PRRSV-2 MLV vaccines administrated via the intramuscular or intradermal route and evaluation of PRRSV transmission upon needle-free and needle delivery. Sci Rep 11, 23107.

³, Salman, M., Lin, H., Suntisukwattana, R. et al. Intradermal needle-free injection prevents African Swine Fever transmission, while intramuscular needle injection does not. Sci Rep 13, 4600 (2023). https://doi.org/10.1038/s41598-023-31199-2